Month: August 2024

Issuance of the Klotho gene-therapy patent will be instrumental in protecting ANEW’s IP for development and commercialization in the U.S. NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) — ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S. -based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the grant and issuance of U.S. Patent No. 12,036,268 (“the 268 patent”) covering the secreted RNA splice variant of the human Klotho gene, referred to as “s-KL”, for the treatment of cognitive and neurodegenerative diseases. The human Klotho gene, sometimes referred to as the “anti-aging” gene, also controls many normal brain and neurologic functions. The Klotho gene-therapy patent in the U.S. is instrumental new intellectual property (“IP”) protecting...

BEIJING, China, Aug. 15, 2024 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it will report its unaudited financial results for the second quarter of 2024 before the U.S. market opens on Wednesday, August 28, 2024. The Company’s management will hold an earnings conference call on Wednesday, August 28, 2024, at 8:00 A.M. U.S. Eastern Time or 8:00 P.M. Beijing/Hong Kong Time on the same day. For participants who wish to join the call, please complete online registration using the link provided below prior to the scheduled call start time. Upon registration, participants will receive the conference call access information, including dial-in numbers, passcode, and a unique access PIN. To join the conference, please dial the number...

The approvals process is anticipated to be completed in the third quarter of 2025Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept). The process to obtain marketing authorization could be completed in the third quarter of 2025. “EMA acceptance takes us a step closer to making AVT06 available in Europe, which is good news for patients and caregivers,” said Joseph McClellan, Chief Scientific Officer of Alvotech....

The approvals process is anticipated to be completed in the third quarter of 2025REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept). The process to obtain marketing authorization could be completed in the third quarter of 2025. “EMA acceptance takes us a step closer to making AVT06 available in Europe, which is good news for patients and caregivers,”...

COMPANY ANNOUNCEMENT no. 62 – 15 August 2024 Yesterday, Karen Dyrskjøt Boesen, CFO, purchased 5,440 DFDS A/S shares. Pursuant to Article 19 (3) of Regulation (EU) no. 596/2014 (Market Abuse Regulation), DFDS A/S is required disclose information regarding transactions in DFDS A/S’ shares by persons discharging managerial responsibilities and persons closely associated with them. Transaction details are reported in the attachment.Contact Søren Brøndholt Nielsen, IR +45 33 42 33 59About DFDS We operate a transport network in and around Europe with an annual revenue of DKK 28bn and 14,000 full-time employees. We move goods in trailers by ferry, road & rail, and we offer complementary and related transport and logistics solutions. We also move car and foot passengers on short sea and overnight ferry routes. DFDS was...

15. august 2024  Pressemeddelelse    Første 6 måneder af 2024: Fortsat stærk vækst i salget af NGAL–tests i USA og fokuseret eksekvering af alle elementer i BioPortos strategi  København, den 15. august, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto eller selskabet) (CPH:BIOPOR), et in-vitro diagnostisk selskab med fokus på tidlig identifikation og vurdering af akut nyreskade (AKI), annoncerede i dag selskabets regnskabsmeddelelse for de første seks måneder af 2024 samt udviklingen i selskabets aktiviteter i regnskabsårets 2. kvartal. Selskabets regnskabsmeddelelse findes her.  Strategiske og driftsmæssige highlights for 2. kvartal 2024: Tocifret salgsvækst inden for alle produktområder drevet af større salg af NGAL-produkter i USA til både eksisterende og nye kunder – bl.a. er selskabets første stående ordre i USA indgået. ...

SINGAPORE, Aug. 15, 2024 (GLOBE NEWSWIRE) — Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”) is pleased to announce first oil production from its Nong Yao C development, in Licence G11/48 (90% operated working interest), offshore Gulf of Thailand.  The first three of the seven Nong Yao C development wells were opened up for oil production on August 15, 2024, with additional wells to be brought online successively thereafter. Ramp up of production volumes will continue in line with the Company’s plan to achieve peak production rates of approximately 11,000 bbls/s within the coming weeks, versus recent rates in the first half of August of approximately 7,200 bbls/d (Valeura working interest share, before royalties). Valeura intends to sustain Nong Yao production rates at approximately...